Compounds
AIKO-150 is the only known candidate drug suitable for co-formulation with an opioid analgesic that will confer both abuse resistance and limited side effects, particularly constipation.
More...
|
News
AIKO Biotechnology, Inc. completes $1.2m Series A financing
More...
|
Articles
6β-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice
Both antagonists produced dose-related blockade of hydrocodone-induced antinociception and inhibition of gastrointestinal transit.
More...
|
